VIRGINIA WINN, MD
Medical Practice at 16 Ave, Denver, CO

License number
Colorado 44374
Category
Medical Practice
Type
Obstetrics & Gynecology
License number
Colorado A65542
Category
Medical Practice
Type
Obstetrics & Gynecology
Address
Address
12605 E 16Th Ave, Denver, CO 80045
Phone
(720) 848-0000
(303) 493-7000

Personal information

See more information about VIRGINIA WINN at radaris.com
Name
Address
Phone
Virginia Winn, age 87
726 S 9Th Ave, Brighton, CO 80601
(303) 659-6663
Virginia Winn, age 78
1055 S High St, Denver, CO 80209
(303) 668-9525
Virginia Winn, age 58
2807 Geneva St, Denver, CO 80238
Virginia Winn
Hayden, CO
(970) 276-3160

Organization information

See more information about VIRGINIA WINN at bizstanding.com

Virginia Winn MD,PHD

12631 E 17 Ave- Academic Ofc, Aurora, CO 80045

Industry:
Obgyn
Phone:
(303) 315-4540 (Phone)
Virginia Dragone Winn

Professional information

See more information about VIRGINIA WINN at trustoria.com
Virginia D Winn Photo 1
Dr. Virginia D Winn - MD (Doctor of Medicine)

Dr. Virginia D Winn - MD (Doctor of Medicine)

Hospitals:
12605 E 16Th Ave, Aurora 80045
1772 Platte St, Denver 80202
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
12605 E 16Th Ave, Aurora 80045
1772 Platte St, Denver 80202
University of Colorado Hospital - Anschutz Inpatient Pavilion
12605 East 16Th Avenue Dr, Aurora 80045
Education:
Medical Schools
University Of Rochester School Of Medicine and Dentistry
Graduated: 1990


Virginia Winn Photo 2
Biomarkers For Preeclampsia

Biomarkers For Preeclampsia

US Patent:
2008023, Sep 25, 2008
Filed:
Feb 20, 2008
Appl. No.:
12/034458
Inventors:
Susan J. Fisher - San Francisco CA, US
Virginia D. Winn - Denver CO, US
Ronit Haimov-Kochman - Mevasseret Zion, IL
Assignee:
REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
C12Q 1/68, G01N 33/566, G01N 33/50, G01N 33/567
US Classification:
435 6, 436501, 436 94, 435 721
Abstract:
The present invention provides methods for predicting the development of and diagnosing preeclampsia, providing a prognosis, and predicting recurrence of the disease using molecular markers that are overexpressed or underexpressed in preeclampia. Also provided are methods to identify compounds that are useful for the treatment or prevention of preeclampsia.